Aerie Pharmaceuticals, Inc.
Posted on: September 9, 2014
By: wordpress
With: Comments Off on Aerie Pharmaceuticals, Inc.
Exclusive financial advisor to Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to enter into a $125m secured convertible debt facility agreement with Deerfield Capital Management for continued development of product pipeline (Rhopressa™ and Roclatan™), general corporate purposes, and strategic growth opportunities